Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis

Summary

This study is a multicenter, randomized, double-blind study. There are three dosage groups: Hemay005 45 mg BID group, 60 mg BID group or placebo group, with 36 patients in each dosage group. All patients will enter a 12-week double-blind treatment period. All subjects who have received the investigational drug should be subjected to a 4-week observation after the end of treatment.

Timeline

Start

2022-11-08

Primary completion

2026-12-30

Completion

2026-12-30

Drugs

Indications